PegIFN-lambda shows superior virological response and improved safety than PegIFN-alpha-2a

Could PegIFN-lambda become the future standard of care in HCV treatment?

2011-04-03

(Press-News.org) Berlin, Germany, 02 April 2011: Highly exciting new data presented today at the International Liver CongressTM found Pegylated Interferon-lambda (PegIFN-lambda) shows superior virological response in HCV patients of genotypes 1-4, with improved safety and tolerability, compared to Pegylated Interferon-alpha (PegIFN-alpha-2a), the current standard of care in chronic HCV.1

The study results are so important because they show PegIFN-lambda could provide relief for the 20% of HCV patients who have to undergo dose reduction, or cease treatment, on PegIFN-alpha-2a – a part of the current HCV standard of care.2

The trial shows that PegIFN-lambda provides higher rapid virological response (RVR) and complete early virological response (cEVR) than PegIFN-alpha-2a, even in patients with an unfavourable IL28B genotype – which predisposes patients to be resistant to treatment.

Both RVR and cEVR are important markers of a drug's ability to combat HCV infection: RVR is measured as undetectable HCV RNA at week 4 of therapy, maintained up to end of treatment; cEVR is detectable HCV RNA at week 4, but undetectable at week 12, maintained up to end of treatment.

Results at week 12 of the trial show that those HCV genotype 1 and 4 patients given 180µg of PegIFN-lambda achieved RVR 14.7% of the time and cEVR 55.9% of time, compared to 5.8% RVR and 37.9% cEVR in patients given the same dose of PegIFN-alpha-2a.

The study also found PegIFN-lambda was associated with fewer hematologic (blood cell) toxicities, flu-like symptoms, musculoskeletal symptoms, dose reductions and premature discontinuations than the same dose of PegIFN-alpha-2a. However, in the higher dose groups elevations of ALT and bilirubin were observed which may represent drug related toxicity.

Professor Heiner Wedemeyer, EASL's Secretary General, commented: "These are clearly very early results but the combination of better virological response and fewer side effects makes these very exciting findings. The percentage of current HCV patients that have to cease treatment, or have their dose lowered, due to the side effects associated with PegIFN-alpha-2a is high. We look forward to seeing the sustained virological responses, which will inform us whether PegIFN-lambda could be used as a replacement for PegIFN-lambda in the future."

In the ongoing randomized phase-IIB trial, 526 treatment-naïve HCV patients received ribavirin with weekly subcutaneous PegIFN-alpha-2a – a 180µg dose or PegIFN-lambda – either a 120, 180 or 240µg doses.

In HCV genotype 2 and 3 patients, 180µg of PegIFN-lambda led to 75.9% RVR and 96.6% cEVR, compared to 31% RVR and 86.2% cEVR for the same dose of PegIFNα-2a. PegIFN-lambda exerts its antiviral effects through a different receptor to PegIFN-alpha-2a.1

### Notes to Editors

About EASL EASL is the leading European scientific society involved in promoting research and education in hepatology. EASL attracts the foremost hepatology experts and has an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in European liver policy.

EASL's main focus on education and research is delivered through numerous events and initiatives, including: The International Liver CongressTM which is the main scientific and professional event in hepatology worldwide Meetings including Monothematic and Special conferences, Post Graduate courses and other endorsed meetings that take place throughout the year Clinical and Basic Schools of Hepatology, a series of events covering different aspects in the field of hepatology Journal of Hepatology published monthly Participation in a number of policy initiatives at European level

About The International Liver CongressTM 2011 The International Liver Congress™ 2011, the 46th annual meeting of the European Association for the study of the Liver, is being held at the Internationales Congress Centrum, Berlin, Germany from March 30 – April 3, 2011. The congress annually attracts over 7,500 clinicians and scientists from around the world and provides an opportunity to hear the latest research, perspectives and treatments of liver disease from principal experts in the field.

References 1. Zeuzem S et al. Pegylated Interferon-lambda (PegIFN-λ) shows superior viral response with improved safety and tolerability versus PegIFNα-2a in HCV patients (G1/2/3/4): Emerge Phase IIB through week 12. Abstract presented at The International Liver CongressTM 2011. http://www1.easl.eu/easl2011/program/Orals/422.htm

2. http://www.thebody.com/content/art1705.html. Accessed 11.03.2011

ELSE PRESS RELEASES FROM THIS DATE:

LateRooms.com - Top Female Surfers Set for Sydney's Commonwealth Bank Beachley Classic

2011-04-03

The world's top female surfers will be heading to Sydney in the coming weeks to face off at the 2011 Commonwealth Bank Beachley Classic. Each of the Association of Surfing Professionals' (ASP's) top 17-ranked women will battle it out for a share of the AU$110,000 prize pot at the event. Among the stars set to compete are four-time world champion Stephanie Gilmore and up-and-coming world tour rookies Laura Enever and Tyler Wright. Gilmore is likely to start as one of the favourites, having taken last year's Beachley Classic title by beating fellow Australian Sally ...

Quadruple therapy shows 100 percent SVR for HCV patients previously unresponsive to treatment

2011-04-03

Berlin, Germany, Saturday 02 April 2011: Exciting new data presented today at the International Liver CongressTM 2011 show that quadruple therapy in chronic hepatitis C (HCV) patients suppressed the emergence of resistant variants and resulted in a 100% rate of sustained virological response - undetectable HCV RNA - 12 weeks after treatment (SVR12).1 In the quadruple therapy study, HCV patients were given four drugs in combination; pegylated Interferon-alpha (PegIFN-alpha); ribavirin (RBV); and two different direct-acting antivirals (DAAs) BMS-650032 (an HCV NS3 protease ...

Genetic variation cuts bladder cancer risk, protects chromosome tips

2011-04-03

ORLANDO - A common genetic variation links to both bladder cancer risk and to the length of protective caps found on the ends of chromosomes, scientists at The University of Texas MD Anderson Cancer Center reported today at the AACR 102nd Annual Meeting. These endings or tips, called telomeres, guard against chromosomal damage and genomic instability that can lead to cancer and other diseases. "We found a single point of variation in the genome strongly associated with a 19 percent decrease in bladder cancer risk. The same variant also is linked to longer telomeres, ...

LateRooms.com - Enter a Team in the Gold Coast Beach Soccer Challenge

2011-04-03

Sports fans will have the chance to put their beach soccer skills to the test in a tournament on the Gold Coast next month. The game may be relatively new to Australia but it has a huge following overseas, having first been played on the sandy stretches of Rio de Janeiro more than 30 years ago. Flamboyant former Manchester United and France star Eric Cantona's love of beach soccer has helped bring it to a global audience in over 170 countries, making it one of the world's fastest-growing sports. Youngsters and adults have been invited to enter their own teams in ...

Spring Means a Spring Clean with the Help of HSS Hire

2011-04-03

As spring begins, it is time to start clearing your garden of all the unwanted winter mess which has piled up over the previous months. It's not just the garden either, as the rest of your home is probably due a traditional 'spring clean', so why not let leading tool and equipment hire specialists, HSS Hire help you out? HSS Hire, the award-winning tool and equipment hire company, has an extensive range of items to help with a wide range of indoor and outdoor tasks. From carpet cleaners to lawnmowers, ladders to drills, HSS Hire is on hand to help. Starting outdoors ...

LateRooms.com - ASO Plays Miles Davis Tribute Coming to Adelaide

2011-04-03

The Adelaide Symphony Orchestra (ASO) will pay tribute to Miles Davis with two performances in the South Australia capital in May 2011. One of the most influential musicians of the 20th century, Davis was at the forefront of many major developments in jazz, including bebop, hard bop and jazz fusion. His ensembles also helped to launch the careers of many other well-known artists such as JJ Johnson, Kai Winding and Gerry Mulligan. Davis's career spanned 50 years, during which he released seminal albums like First Miles, Kind of Blue and Someday My Prince Will Come. Acclaimed ...

Antidepressants linked to thicker arteries

2011-04-03

Antidepressant use has been linked to thicker arteries, possibly contributing to the risk of heart disease and stroke, in a study of twin veterans. The data is being presented Tuesday, April 5 at the American College of Cardiology meeting in New Orleans. Depression can heighten the risk for heart disease, but the effect of antidepressant use revealed by the study is separate and independent from depression itself, says first author Amit Shah, MD, a cardiology fellow at Emory University School of Medicine. The data suggest that antidepressants may combine with depression ...

Research on antibiotic use, drug resistant organisms and effectiveness of electronic faucets

2011-04-03

WHAT: A special media phone briefing with leading infectious disease scientists and healthcare-associated infection experts who will headline the 2011 Society for Healthcare Epidemiology of America's (SHEA) Annual Meeting WHO: Arjun Srinivasan, MD, Associate Director of Healthcare-associated Infection Prevention Programs at the Centers for Disease Control and Prevention Steven Gordon, MD, President, Society for Healthcare Epidemiology of America Makoto Jones, MD, Salt Lake City VA Healthcare System Dawn Terashita, MD, MPH, Los Angeles County Department of ...

Bingo Wonga, One of the Leading UK Bingo Review Websites, Launches New UK Lotto Results Service

2011-04-03

Bingo Wonga will offer a new lotto results section which will feature all the latest UK Lotto draws including Lotto, Euro Millions, Thunderball, Plus 5, Daily Play and Hotpicks. The new section will also contain a history of results for each draw. Bingo Wonga was launched during May 2010 and in less than a year has become one of the most popular online bingo review sites. Unlike most other bingo review sites, Bingo Wonga only promote the very best UK bingo brands such as Sky Bingo, Sky Vegas and Virgin Bingo. Bingo Wonga also make available to their readers a large ...

Hypothermia proves successful in younger cardiac patients too

2011-04-03

Young adult patients with genetic heart diseases, such as hypertrophic cardiomyopathy (HCM), substantially benefitted from therapeutic hypothermia, which could further extend the role for this treatment strategy in new patient populations, according to a scientific presentation at the American College of Cardiology (ACC) Scientific Sessions in New Orleans, April 1-3. In patients with HCM, despite rapid cardiopulmonary resuscitation (CPR) with defibrillation, survival following out-of-hospital cardiac arrest has been particularly unfavorable, explained the study authors. ...

LAST 30 PRESS RELEASES:

Evaluating performance and agreement of coronary heart disease polygenic risk scores

Heart failure in zero gravity— external constraint and cardiac hemodynamics

Amid record year for dengue infections, new study finds climate change responsible for 19% of today’s rising dengue burden

New study finds air pollution increases inflammation primarily in patients with heart disease

AI finds undiagnosed liver disease in early stages

The American Society of Tropical Medicine and Hygiene and the Bill & Melinda Gates Foundation announce new research fellowship in malaria genomics in honor of professor Dominic Kwiatkowski